Limits...
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.

Gao S, Jiang J, Li P, Song H, Wang W, Li C, Kong D - Biomed Res Int (2015)

Bottom Line: No inhibition of breast tumour progression was detected.However, tumour necrosis was significantly increased in the metformin-treated group, accompanied by decreased capillary formation within the tumours.Thus, despite the lack of short-term benefit of metformin against tumour progression, a preventive role of metformin against breast cancer was implicated, which is at partially attributable to the attenuation of tumour angiogenesis.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, China.

ABSTRACT
Metformin is one of the most widely prescribed antidiabetics for type 2 diabetes. A critical role of metformin against tumorigenesis has recently been implicated, although several studies also reported the lack of anticancer property of the antidiabetics. Given the controversies regarding the potential role of metformin against tumour progression, the effect of metformin against breast, cervical, and ovarian tumour cell lines was examined followed by in vivo assessment of metformin on tumour growth using xenograft breast cancer models. Significant inhibitory impact of metformin was observed in MCF-7, HeLa, and SKOV-3 cells, suggesting an antiproliferative property of metformin against breast, cervical, and ovarian tumour cells, respectively, with the breast tumour cells, MCF-7, being the most responsive. In vivo assessment was subsequently carried out, where mice with breast tumours were treated with metformin (20 mg/kg body weight) or sterile PBS solution for 15 consecutive days. No inhibition of breast tumour progression was detected. However, tumour necrosis was significantly increased in the metformin-treated group, accompanied by decreased capillary formation within the tumours. Thus, despite the lack of short-term benefit of metformin against tumour progression, a preventive role of metformin against breast cancer was implicated, which is at partially attributable to the attenuation of tumour angiogenesis.

Show MeSH

Related in: MedlinePlus

In vivo assessment of metformin treatment on tumour growth. Metformin (20 mg/kg body weight; Metformin group) or sterile PBS (Control group) was injected locally to mice with breast carcinoma for 15 consecutive days. (a) Average tumour size and (b) body weight were monitored and plotted against time for Metformin (closed circle) and Control group (open circle). Total changes of tumour volume (c) and body weight (d) were also presented as area under curve (AUC). Data are presented as means ± SD, n = 4-5.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4389975&req=5

fig2: In vivo assessment of metformin treatment on tumour growth. Metformin (20 mg/kg body weight; Metformin group) or sterile PBS (Control group) was injected locally to mice with breast carcinoma for 15 consecutive days. (a) Average tumour size and (b) body weight were monitored and plotted against time for Metformin (closed circle) and Control group (open circle). Total changes of tumour volume (c) and body weight (d) were also presented as area under curve (AUC). Data are presented as means ± SD, n = 4-5.

Mentions: Given the high prevalence of breast cancer and the current controversies concerning the exact impact of metformin use against breast carcinoma, human xenograft breast tumour mouse models were used in the present study for in vivo evaluation. Thus, local injection of PBS (Control group) or metformin (20 mg/kg body weight; Metformin group) was administered daily at the tumour site for two weeks. No changes of tumour volume were detectable between the control and metformin-treated groups (Figures 2(a) and 2(b)). No attenuation of tumour progression was observed either as superimposable tumour growth profiles were obtained from both groups (Figure 2(a)). In addition, no significant difference in animal body weight was detected between the two groups (Figure 2(b)).


Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.

Gao S, Jiang J, Li P, Song H, Wang W, Li C, Kong D - Biomed Res Int (2015)

In vivo assessment of metformin treatment on tumour growth. Metformin (20 mg/kg body weight; Metformin group) or sterile PBS (Control group) was injected locally to mice with breast carcinoma for 15 consecutive days. (a) Average tumour size and (b) body weight were monitored and plotted against time for Metformin (closed circle) and Control group (open circle). Total changes of tumour volume (c) and body weight (d) were also presented as area under curve (AUC). Data are presented as means ± SD, n = 4-5.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4389975&req=5

fig2: In vivo assessment of metformin treatment on tumour growth. Metformin (20 mg/kg body weight; Metformin group) or sterile PBS (Control group) was injected locally to mice with breast carcinoma for 15 consecutive days. (a) Average tumour size and (b) body weight were monitored and plotted against time for Metformin (closed circle) and Control group (open circle). Total changes of tumour volume (c) and body weight (d) were also presented as area under curve (AUC). Data are presented as means ± SD, n = 4-5.
Mentions: Given the high prevalence of breast cancer and the current controversies concerning the exact impact of metformin use against breast carcinoma, human xenograft breast tumour mouse models were used in the present study for in vivo evaluation. Thus, local injection of PBS (Control group) or metformin (20 mg/kg body weight; Metformin group) was administered daily at the tumour site for two weeks. No changes of tumour volume were detectable between the control and metformin-treated groups (Figures 2(a) and 2(b)). No attenuation of tumour progression was observed either as superimposable tumour growth profiles were obtained from both groups (Figure 2(a)). In addition, no significant difference in animal body weight was detected between the two groups (Figure 2(b)).

Bottom Line: No inhibition of breast tumour progression was detected.However, tumour necrosis was significantly increased in the metformin-treated group, accompanied by decreased capillary formation within the tumours.Thus, despite the lack of short-term benefit of metformin against tumour progression, a preventive role of metformin against breast cancer was implicated, which is at partially attributable to the attenuation of tumour angiogenesis.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, China.

ABSTRACT
Metformin is one of the most widely prescribed antidiabetics for type 2 diabetes. A critical role of metformin against tumorigenesis has recently been implicated, although several studies also reported the lack of anticancer property of the antidiabetics. Given the controversies regarding the potential role of metformin against tumour progression, the effect of metformin against breast, cervical, and ovarian tumour cell lines was examined followed by in vivo assessment of metformin on tumour growth using xenograft breast cancer models. Significant inhibitory impact of metformin was observed in MCF-7, HeLa, and SKOV-3 cells, suggesting an antiproliferative property of metformin against breast, cervical, and ovarian tumour cells, respectively, with the breast tumour cells, MCF-7, being the most responsive. In vivo assessment was subsequently carried out, where mice with breast tumours were treated with metformin (20 mg/kg body weight) or sterile PBS solution for 15 consecutive days. No inhibition of breast tumour progression was detected. However, tumour necrosis was significantly increased in the metformin-treated group, accompanied by decreased capillary formation within the tumours. Thus, despite the lack of short-term benefit of metformin against tumour progression, a preventive role of metformin against breast cancer was implicated, which is at partially attributable to the attenuation of tumour angiogenesis.

Show MeSH
Related in: MedlinePlus